Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemothe… (NCT07273396) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
53 participantsStarted 2026-01-01
Plain-language summary
The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.
Who can participate
Age range19 Years – 85 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age: Women aged 19-85 years.
✓. Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer.
✓. Platinum Status:
✓. Prior Therapies: ≥2 prior intravenous chemotherapies (may include paclitaxel).
✓. Treatment Options: Unresponsive to/ineligible for standard therapies (e.g., intolerance, hypersensitivity) and ineligible for surgical resection.
✓. Measurable Disease: ≥1 measurable/evaluable peritoneal lesion per RECIST 1.1.